In vivo imaging of molecular targets and their function in endocrinology

Journal of Molecular Endocrinology

Volumn 40, Issue 5-6, 2008, Pages 253-261

  Burdette, Joanna E ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; BIOLOGICAL MARKER; CARBON 11; CELL SURFACE RECEPTOR; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; LUTETIUM 177; MATRIX METALLOPROTEINASE; PENTETREOTIDE IN 111; SEROTONIN; TAMOXIFEN; TRASTUZUMAB; YTTRIUM 90;

AMINO ACID METABOLISM; BIOLUMINESCENCE; BREAST CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG TARGETING; ENDOCRINE DISEASE; ENDOCRINOLOGY; ENZYME ACTIVITY; FLUORESCENCE; GLUCOSE METABOLISM; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION;

AMINO ACIDS; ANIMALS; ENDOCRINOLOGY; GLUCOSE; HUMANS; IMAGING, THREE-DIMENSIONAL; PROMOTER REGIONS (GENETICS); RECEPTORS, CELL SURFACE;

EID: 45749103746     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/JME-07-0170     Document Type: Review

References (69)

1. Acton PD & Zhou R 2005 Imaging reporter genes for cell tracking with PET and SPECT. Quarterly Journal of Nuclear Medicine and Molecular Imaging 49 349-360.
2. Allen MJ & Meade TJ 2003 Synthesis and visualization of a membrane-permeable MRI contrast agent. Journal of Biological Inorganic Chemistry 8 746-750.
3. Allen MJ & Meade TJ 2004. Metal Ions in Biological Systems, New York: Fontis Media.
4. Allen MJ, MacRenaris KW, Venkatasubramanian PN & Meade TJ 2004 Cellular delivery of MRI contrast agents. Chemistry & Biology 11 301-307.
5. Artemov D, Mori N, Okollie B & Bhujwalla ZM 2003a MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magnetic Resonance in Medicine 49 403-408.
6. Artemov D, Mori N, Ravi R & Bhujwalla ZM 2003b Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Research 63 2723-2727.
7. Becherer A, Szabo M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M, Kurtaran A, Dudczak R & Kletter K 2004 Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET. Journal of Nuclear Medicine 45 1161-1167.
8. Blasberg R 2002 PET imaging of gene expression. European Journal of Cancer 38 2137-2146.
9. Van Den Bossche B & Van de Wiele C 2004 Receptor imaging in oncology by means of nuclear medicine: current status. Journal of Clinical Oncology 22 3593-3607.
10. 18F-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo. Quarterly Journal of Nuclear Medicine and Molecular Imaging 51 24-32.
11. Cai W, Niu G & Chen X 2007 Multimodality imaging of the HER-kinase axis in cancer. European Journal of Nuclear Medicine and Molecular Imaging 35 186-208.
12. Ciana P, Di Luccio G, Belcredito S, Pollio G, Vegeto E, Tatangelo L, Tiveron C & Maggi A 2001 Engineering of a mouse for the in vivo profiling of estrogen receptor activity. Molecular Endocrinology 15 1104-1113.
13. Ciana P, Raviscioni M, Mussi P, Vegeto E, Que I, Parker MG, Lowik C & Maggi A 2003 In vivo imaging of transcriptionally active estrogen receptors. Nature Medicine 9 82-86.
14. Dickinson ME 2006 Multimodal imaging of mouse development: tools for the postgenomic era. Developmental Dynamics 235 2386-2400.
15. Doubrovin M, Ponomarev V & Blasberg RG 2004 PET-based reporter gene imaging. Assessment of endogenous molecular-genetic events. IEEE Engineering in Medicine and Biology Magazine 23 38-50.
16. Eriksson B, Orlefors H, Oberg K, Sundin A, Bergstrom M & Langstrom B 2005 Developments in PET for the detection of endocrine tumours. Best Practice and Research. Clinical Endocrinology and Metabolism 19 311-324.
17. Van Essen M, Krenning EP, De Jong M, Valkema R & Kwekkeboom DJ 2007 Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncologica 46 723-734.
18. Faley SL, Takahashi K, Crooke CE, Beckham JT, Tomemori T, Shappell SB, Jansen ED & Takahashi T 2007 Bioluminescence imaging of vascular endothelial growth factor promoter activity in murine mammary tumorigenesis. Molecular Imaging 6 331-339.
19. 18F]CbR) as potential positron emission tomography-compatible apoptosis imaging agent. Quarterly Journal of Nuclear Medicine and Molecular Imaging 51 67-73.
20. Frullano L & Meade TJ 2007 Multimodal MRI contrast agents. Journal of Biological Inorganic Chemistry 12 939-949.
21. Frullano L, Tejerina B & Meade TJ 2006 Synthesis and characterization of a doxorubicin-Gd(III) contrast agent conjugate: a new approach toward prodrug-procontrast complexes. Inorganic Chemistry 45 8489-8491.
22. Funovics MA, Kapeller B, Hoeller C, Su HS, Kunstfeld R, Puig S & Macfelda K 2004 MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magnetic Resonance Imaging 22 843-850.
23. 18F]FDG PET in clinical oncology. Lancet Oncology 8 822-830.
24. Hanaoka K, Lubag AJ, Castillo-Muzquiz A, Kodadek T & Sherry AD 2008 The detection limit of a Gd(3+)-based T(1) agent is substantially reduced when targeted to a protein microdomain. Magnetic Resonance Imaging (Epub Jan 31).
25. Hani T, Tachibe T, Shingai S, Kamada N, Ueda O & Jishage K 2006 Fertility of mice receiving vitrified adult mouse ovaries. Reproduction 131 681-687.
26. de Herder WW, Kwekkeboom DJ, Valkema K, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ & Krenning EP 2005 Neuroendocrine tumors and somatostatin: imaging techniques. Journal of Endocrinological Investigation 28 132-136.
27. Herschman HR 2004 PET reporter genes for noninvasive imaging of gene therapy, cell tracking and transgenic analysis. Critical Reviews in Oncology/Hematology 51 191-204.
28. Hostetler ED, Jonson SD, Welch MJ & Katzenellenbogen JA 1999 Synthesis of 2-[(18)F]fluoroestradiol, a potential diagnostic imaging agent for breast cancer: strategies to achieve nucleophilic substitution of an electron-rich aromatic ring with [(18)F]F(-). Journal of Organic Chemistry 64 178-185.
29. 18F-FDG PET/CT can make a difference in diagnosis and patient care. Journal of Nuclear Medicine 48 28S-35S.
30. Jonson SD & Welch MJ 1998 PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Quarterly Journal of Nuclear Medicine 42 8-17.
31. 18F]fluoromoxestrol in isolated hepatocytes. Nuclear Medicine and Biology 26 123-130.
32. Josephson L, Kircher MF, Mahmood U, Tang Y & Weissleder R 2002 Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjugate Chemistry 13 554-560.
33. Kaarbo M, Klokk TI & Saatcioglu F 2007 Androgen signaling and its interactions with other signaling pathways in prostate cancer. Bioessays 29 1227-1238.
34. Kircher MF, Mahmood U, King RS, Weissleder R & Josephson L 2003 A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Research 63 8122-8125.
35. Krausz Y & Israel O 2006 Single-photon emission computed tomography/ computed tomography in endocrinology. Seminars in Nuclear Medicine 36 267-274.
36. 18F]FES) in ER positive breast cancer patients. Journal of Pharmacy & Pharmaceutical Sciences 10 256s-265s.
37. Lee J, Zylka MJ, Anderson DJ, Burdette JE, Woodruff TK & Meade TJ 2005 A steroid-conjugated contrast agent for magnetic resonance imaging of cell signaling. Journal of the American Chemical Society 127 13164-13166.
38. Lee J, Burdette JE, MacRenaris KW, Mustafi D, Woodruff TK & Meade TJ 2007 Rational design, synthesis, and biological evaluation of progesterone-modified MRI contrast agents. Chemistry & Biology 14 824-834.
39. Lemmen JG, Arends RJ, van der Saag PT & van der Burg B 2004a In vivo imaging of activated estrogen receptors in utero by estrogens and bisphenol A. Environmental Health Perspectives 112 1544-1549.
40. Lemmen JG, Arends RJ, van Boxtel AL, van der Saag PT & van der Burg B 2004b Tissue- and time-dependent estrogen receptor activation in estrogen reporter mice. Journal of Molecular Endocrinology 32 689-701.
41. Lewington VJ & Clarke SE 2001 Isotopic evaluation and therapy in patients with malignant endocrine disease. Best Practice and Research. Clinical Endocrinology and Metabolism 15 225-239.
42. Louie A 2006 Design and characterization of magnetic resonance imaging gene reporters. Methods in Molecular Medicine 124 401-417.
43. Louie AY, Huber MM, Ahrens ET, Rothbacher U, Moats R, Jacobs RE, Fraser SE & Meade TJ 2000 In vivo visualization of gene expression using magnetic resonance imaging. Nature Biotechnology 18 321-325.
44. 18F] fluorodeoxyglucose and beyond. Clinical Cancer Research 13 3460-3469.
45. Mazaud Guittot S, Tetu A, Legault E, Pilon N, Silversides DW & Viger RS 2007 The proximal Gata4 promoter directs reporter gene expression to sertoli cells during mouse gonadal development. Biology of Reproduction 76 85-95.
46. Nagel SC, Hagelbarger JL & McDonnell DP 2001 Development of an ER action indicator mouse for the study of estrogens, selective ER modulators (SERMs), and Xenobiotics. Endocrinology 142 4721-4728.
47. 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomedicine & Pharmacotherapy 60 409-413.
48. Nishi M, Usuku T, Itose M, Fujikawa K, Hosokawa K, Matsuda KI & Kawata M 2007 Direct visualization of glucocorticoid receptor positive cells in the hippocampal regions using green fluorescent protein transgenic mice. Neuroscience 146 1555-1560.
49. Orlefors H, Sundin A, Ahlstrom H, Bjurling P, Bergstrom M, Lilja A, Langstrom B, Oberg K & Eriksson B 1998 Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. Journal of Clinical Oncology 16 2534-2541.
50. 11C-5-hydroxytryptophan positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging 33 60-65.
51. Parent EE, Carlson KE & Katzenellenbogen JA 2007 Synthesis of 7alpha-(fluoromethyl)dihydrotestosterone and 7alpha-(fluoromethyl)nortestosterone, structurally paired androgens designed to probe the role of sex hormone binding globulin in imaging androgen receptors in prostate tumors by positron emission tomography. Journal of Organic Chemistry 72 5546-5554.
52. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M & Maziere B 1998 FDG accumulation and tumor biology. Nuclear Medicine and Biology 25 317-322.
53. Puri S & Hebrok M 2007 Dynamics of embryonic pancreas development using real-time imaging. Developmental Biology 306 82-93.
54. Rome C, Couillaud F & Moonen CT 2007 Gene expression and gene therapy imaging. European Radiology 17 305-319.
55. Rufini V, Calcagni ML & Baum RP 2006 Imaging of neuroendocrine tumors. Seminars in Nuclear Medicine 36 228-247.
56. Seevinck PR, Seppenwoolde JH, de Wit TC, Nijsen JF, Beckman FJ, van Het Schip AD & Bakker CJ 2007 Factors affecting the sensitivity and detection limits of MRI, CT, and SPECT for multimodal diagnostic and therapeutic agents. Anti-Cancer Agents in Medicinal Chemistry 7 317-334.
57. Skaddan MB, Wust FR, Jonson S, Syhre R, Welch MJ, Spies H & Katzenellenbogen JA 2000 Radiochemical synthesis and tissue distribution of Tc-99m-labeled 7alpha-substituted estradiol complexes. Nuclear Medicine and Biology 27 269-278.
58. Sundin A, Eriksson B, Bergstrom M, Langstrom B, Oberg K & Orlefors H 2004 PET in the diagnosis of neuroendocrine tumors. Annals of the New York Academy of Sciences 1014 246-257.
59. Sundin A, Garske U & Orlefors H 2007 Nuclear imaging of neuroendocrine tumours. Best Practice and Research. Clinical Endocrinology and Metabolism 21 69-85.
60. 11C]vorozole. Nuclear Medicine and Biology 33 599-605.
61. Takahashi N, Yang DJ, Kurihara H, Borne A, Kohanim S, Oh CS, Mawlawi O & Kim EE 2007 Functional imaging of estrogen receptors with radiolabeled-GAP-EDL in rabbit endometriosis model. Academic Radiology 14 1050-1057.
62. Tamm EP, Kim EE & Ng CS 2007 Imaging of neuroendocrine tumors. Hematology/Oncology Clinics of North America 21 409-432 vii.
63. Tohma T, Okazumi S, Makino H, Cho A, Mochiduki R, Shuto K, Kudo H, Matsubara K, Gunji H & Ochiai T 2005 Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer. Hepatogastroenterology 52 486-490.
64. Torigian DA, Huang SS, Houseni M & Alavi A 2007 Functional imaging of cancer with emphasis on molecular techniques. CA: A Cancer Journal for Clinicians 57 206-224.
65. Wang M, Lacy G, Gao M, Miller KD, Sledge GW & Zheng QH 2007 Synthesis of carbon-11 labeled sulfonanilide analogues as new potential PET agents for imaging of aromatase in breast cancer. Bioorganic and Medicinal Chemistry Letters 17 332-336.
66. Van de Wiele C, Cocquyt V, Van den Broecke R, De Vos F, Van Belle S, Dhaene K, Slegers G & Dierckx RA 2001 Iodine-labeled tamoxifen uptake in primary human breast carcinoma. Journal of Nuclear Medicine 42 1818-1820.
67. Wurdinger T, Badr C, Pike L, de Kleine R, Weissleder R, Breakefield XO & Tannous BA 2008 A secreted luciferase for ex vivo monitoring of in vivo processes. Nature Methods 5 171-173.
68. Zhang W, Feng JQ, Harris SE, Contag PR, Stevenson DK & Contag CH 2001 Rapid in vivo functional analysis of transgenes in mice using whole body imaging of luciferase expression. Transgenic Research 10 423-434.
69. 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. Journal of Nuclear Medicine 46 675-682.